Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (terbuka di window baru)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Sumber‎: Cancer 2013;119(21):3784-7.

Index‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (terbuka di window baru)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (terbuka di window baru)

Chakrabarti S, Varma S, Singh S, Kumari S

Sumber‎: Eur J Haematol 1998;60(5):313-4.

Index‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (terbuka di window baru)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (terbuka di window baru)

Delaney M, Matthews DC, Gernsheimer TB

Sumber‎: Pediatr Blood Cancer 2017;64(12):e26641.

Index‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (terbuka di window baru)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (terbuka di window baru)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Sumber‎: J Urol 2010;184(3):1152-7.

Index‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (terbuka di window baru)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (terbuka di window baru)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Sumber‎: Leuk Lymphoma 1995;19(1-2):141-4.

Index‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (terbuka di window baru)

Pediatric off-label use of recombinant factor VIIa. (terbuka di window baru)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Sumber‎: Pediatrics 2009;123(3):1066-72.

Index‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (terbuka di window baru)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (terbuka di window baru)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Sumber‎: Indian J Pediatr 2011;78(8):961-8.

Index‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (terbuka di window baru)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (terbuka di window baru)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Sumber‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Index‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (terbuka di window baru)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (terbuka di window baru)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Sumber‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Index‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (terbuka di window baru)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (terbuka di window baru)

Das P, Carcao M, Hitzler J

Sumber‎: Pediatr Blood Cancer 2006;47(2):206-9.

Index‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (terbuka di window baru)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (terbuka di window baru)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Sumber‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Index‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (terbuka di window baru)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (terbuka di window baru)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Sumber‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Index‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (terbuka di window baru)

Off-label use of recombinant factor VIIa in pediatric patients. (terbuka di window baru)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Sumber‎: Pediatrics 2012;129(6):e1533-40.

Index‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (terbuka di window baru)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (terbuka di window baru)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Sumber‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Index‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (terbuka di window baru)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (terbuka di window baru)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Sumber‎: Med Oncol 2010;27(1):16-9.

Index‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (terbuka di window baru)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (terbuka di window baru)

Ucar C, Caliskan U

Sumber‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Index‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (terbuka di window baru)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (terbuka di window baru)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Sumber‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Index‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (terbuka di window baru)

The use of DDAVP in children with bleeding disorders. (terbuka di window baru)

Ben-Ami T, Revel-Vilk S

Sumber‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Index‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (terbuka di window baru)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (terbuka di window baru)

Kobrinsky NL, Tulloch H

Sumber‎: J Pediatr 1988;112(6):993-6.

Index‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (terbuka di window baru)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (terbuka di window baru)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Sumber‎: J Pediatr Surg 2013;48(3):689-94.

Index‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (terbuka di window baru)